Pediatrix Medical Group, Inc. (MD)
NYSE • Healthcare
Last close at September 10, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Pediatrix Medical Group, Inc. keeps $8 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 2
in 52 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Pediatrix Medical Group topped consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported Aug. 4. Revenue rose 4% to about $487.8 million from $468.8 million a year ago, about 2% above the $478.5 million estimate, while adjusted EPS came in at $0.63 versus $0.59 expected and was up 18.9% from $0.53 a year earlier. Net income increased 1.5% to about $39.8 million from $39.3 million a year ago, operating income reached about $56.9 million, operating cash flow was about $125.3 million, and the company repurchased about $42.7 million of stock. Next-period consensus calls for EPS of $0.62 on revenue of $493.7 million.
About Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. provides physician services for mothers, newborns, and children in the healthcare sector and trades on the NYSE as MD. The company generated $1.9 billion of revenue in FY2025 through a network of specialty medical practices and hospital-based support across the United States and Puerto Rico.
Today's Snapshot
The day ended with MD 1.3% lower at 26.75, in line with a weaker sector. MD closed within 4.3% of its 52-week high of 27.94.
Trading Volume
Below 10d avg (653.0K)
561.5K
vs S&P 500 Today
Underperforming Market
-0.69%
Updated: September 10, 2026 at 20:11 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$23.15 - $26.80Buy
- RSI (14)52.52Neutral
- Stochastic %K (14, 3, 3)79.50Neutral
- MACD Level (12, 26)0.21Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.